CONDENSED STATEMENTS OF OPERATIONS (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Revenue:
License revenue	$ 150,000	$ 0	$ 150,000	$ 0
Expenses:
Research and development	1,886,652	3,073,059	6,707,360	5,118,868
General and administrative	2,026,602	2,060,266	4,174,061	4,705,376
Total expenses	3,913,254	5,133,325	10,881,421	9,824,244
Loss before other income	(3,763,254)	(5,133,325)	(10,731,421)	(9,824,244)
Other income:
Interest income	50,270	79,687	105,699	172,718
Other income, net	15,619	28,530	52,650	35,696
Gain on warrant derivative liability	577,290	1,278,884	1,177,762	1,411,577
Gain on sale of affiliate's shares - RXi Pharmaceutical	0	5,040,114	0	8,887,614
Loss before provision for income taxes	(3,120,075)	1,293,890	(9,395,310)	683,361
Provision for income taxes	0	0	0	0
Net income (loss)	(3,120,075)	1,293,890	(9,395,310)	683,361
Other comprehensive income (net of tax)
Unrealized gain on available-for-sale securities	379,260	8,044,091	379,260	8,044,091
Comprehensive income (loss)	$ (2,740,815)	$ 9,337,981	$ (9,016,050)	$ 8,727,452
Basic net income (loss) per share (in dollars per share)	$ (0.03)	$ 0.01	$ (0.09)	$ 0.01
Basic weighted average shares outstanding (in shares)	109,227,069	109,121,022	109,226,683	109,016,952
Diluted net income (loss) per share (in dollars per share)	$ (0.03)	$ 0.01	$ (0.09)	$ 0.01
Diluted weighted average shares outstanding (in shares)	109,227,069	111,587,896	109,226,683	111,934,617